View in EDS

Patient and oncologist preferences for ALK+ advanced non-small cell lung cancer tyrosine kinase inhibitor treatments: a discrete choice experiment in the United States.

Saved in:
Bibliographic Details
Title: Patient and oncologist preferences for ALK+ advanced non-small cell lung cancer tyrosine kinase inhibitor treatments: a discrete choice experiment in the United States.
Authors: Le H; Pfizer, 66 Hudson Blvd E, New York, NY 10001, USA. Electronic address: hannahlepharmd@gmail.com., Coulter J; Pfizer, 66 Hudson Blvd E, New York, NY 10001, USA. Electronic address: joshua.coulter@pfizer.com., Culver K; ALK Positive Inc, 6595 Roswell Road, Suite G2310, Atlanta, GA 30328, USA. Electronic address: ken.culver@alkpositive.org., Cappelleri JC; Pfizer, 66 Hudson Blvd E, New York, NY 10001, USA. Electronic address: joseph.c.cappelleri@pfizer.com., Rifi N; Pfizer, 66 Hudson Blvd E, New York, NY 10001, USA. Electronic address: nada.rifi@pfizer.com., Lu H; Evidera, The Ark, 201 Talgarth Rd, London W6 8BJ, UK. Electronic address: hui.lu@thermofisher.com., Quaife M; Evidera, The Ark, 201 Talgarth Rd, London W6 8BJ, UK. Electronic address: matt.quaife@thermofisher.com., Meginnis K; Evidera, The Ark, 201 Talgarth Rd, London W6 8BJ, UK. Electronic address: keila.meginnis@thermofisher.com., Fernandez GS; Evidera, The Ark, 201 Talgarth Rd, London W6 8BJ, UK. Electronic address: gabriela.fernandez@thermofisher.com., Vaghela S; HealthEcon Consulting, Inc, Ancaster, ON L9G 4L2, Canada. Electronic address: shailja@healthecons.com., Hauber B; Pfizer, 66 Hudson Blvd E, New York, NY 10001, USA. Electronic address: albert.hauber@pfizer.com., Stinchcombe TE; Duke Cancer Institute, DUMC 3198, 25178 Morris Building, Durham, NC 27710, USA. Electronic address: thomas.stinchcombe@duke.edu.
Source: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2026 Jan; Vol. 211, pp. 108850. Date of Electronic Publication: 2025 Nov 21.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8332 (Electronic) Linking ISSN: 01695002 NLM ISO Abbreviation: Lung Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41317687
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Patient and oncologist preferences for ALK+ advanced non-small cell lung cancer tyrosine kinase inhibitor treatments: a discrete choice experiment in the United States.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Le+H%22">Le H</searchLink>; Pfizer, 66 Hudson Blvd E, New York, NY 10001, USA. Electronic address: hannahlepharmd@gmail.com.<br /><searchLink fieldCode="AU" term="%22Coulter+J%22">Coulter J</searchLink>; Pfizer, 66 Hudson Blvd E, New York, NY 10001, USA. Electronic address: joshua.coulter@pfizer.com.<br /><searchLink fieldCode="AU" term="%22Culver+K%22">Culver K</searchLink>; ALK Positive Inc, 6595 Roswell Road, Suite G2310, Atlanta, GA 30328, USA. Electronic address: ken.culver@alkpositive.org.<br /><searchLink fieldCode="AU" term="%22Cappelleri+JC%22">Cappelleri JC</searchLink>; Pfizer, 66 Hudson Blvd E, New York, NY 10001, USA. Electronic address: joseph.c.cappelleri@pfizer.com.<br /><searchLink fieldCode="AU" term="%22Rifi+N%22">Rifi N</searchLink>; Pfizer, 66 Hudson Blvd E, New York, NY 10001, USA. Electronic address: nada.rifi@pfizer.com.<br /><searchLink fieldCode="AU" term="%22Lu+H%22">Lu H</searchLink>; Evidera, The Ark, 201 Talgarth Rd, London W6 8BJ, UK. Electronic address: hui.lu@thermofisher.com.<br /><searchLink fieldCode="AU" term="%22Quaife+M%22">Quaife M</searchLink>; Evidera, The Ark, 201 Talgarth Rd, London W6 8BJ, UK. Electronic address: matt.quaife@thermofisher.com.<br /><searchLink fieldCode="AU" term="%22Meginnis+K%22">Meginnis K</searchLink>; Evidera, The Ark, 201 Talgarth Rd, London W6 8BJ, UK. Electronic address: keila.meginnis@thermofisher.com.<br /><searchLink fieldCode="AU" term="%22Fernandez+GS%22">Fernandez GS</searchLink>; Evidera, The Ark, 201 Talgarth Rd, London W6 8BJ, UK. Electronic address: gabriela.fernandez@thermofisher.com.<br /><searchLink fieldCode="AU" term="%22Vaghela+S%22">Vaghela S</searchLink>; HealthEcon Consulting, Inc, Ancaster, ON L9G 4L2, Canada. Electronic address: shailja@healthecons.com.<br /><searchLink fieldCode="AU" term="%22Hauber+B%22">Hauber B</searchLink>; Pfizer, 66 Hudson Blvd E, New York, NY 10001, USA. Electronic address: albert.hauber@pfizer.com.<br /><searchLink fieldCode="AU" term="%22Stinchcombe+TE%22">Stinchcombe TE</searchLink>; Duke Cancer Institute, DUMC 3198, 25178 Morris Building, Durham, NC 27710, USA. Electronic address: thomas.stinchcombe@duke.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228800805%22">Lung cancer (Amsterdam, Netherlands)</searchLink> [Lung Cancer] 2026 Jan; Vol. 211, pp. 108850. <i>Date of Electronic Publication: </i>2025 Nov 21.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Scientific+Publishers%22">Elsevier Scientific Publishers </searchLink><i>Country of Publication: </i>Ireland <i>NLM ID: </i>8800805 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1872-8332 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201695002%22">01695002 </searchLink><i>NLM ISO Abbreviation: </i>Lung Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41317687
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.lungcan.2025.108850
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 108850
    Titles:
      – TitleFull: Patient and oncologist preferences for ALK+ advanced non-small cell lung cancer tyrosine kinase inhibitor treatments: a discrete choice experiment in the United States.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Le H
      – PersonEntity:
          Name:
            NameFull: Coulter J
      – PersonEntity:
          Name:
            NameFull: Culver K
      – PersonEntity:
          Name:
            NameFull: Cappelleri JC
      – PersonEntity:
          Name:
            NameFull: Rifi N
      – PersonEntity:
          Name:
            NameFull: Lu H
      – PersonEntity:
          Name:
            NameFull: Quaife M
      – PersonEntity:
          Name:
            NameFull: Meginnis K
      – PersonEntity:
          Name:
            NameFull: Fernandez GS
      – PersonEntity:
          Name:
            NameFull: Vaghela S
      – PersonEntity:
          Name:
            NameFull: Hauber B
      – PersonEntity:
          Name:
            NameFull: Stinchcombe TE
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: 2026 Jan
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1872-8332
          Numbering:
            – Type: volume
              Value: 211
          Titles:
            – TitleFull: Lung cancer (Amsterdam, Netherlands)
              Type: main
ResultId 1